Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study

Mileshkin, Linda; Manzyuk, Ludmila; Penel, Nicolas; Burge, Matthew; Piha‐Paul, Sarina A.; Girda, Eugenia; Lopez-Martin, Jose A.; Dongen, Marloes G J van; Italiano, Antoîne; Liu, Xu; Jin, Fan; Norwood, Kevin; Ott, Patrick A.

doi:10.1016/j.ygyno.2022.01.029

Cited by 24 publications

(31 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…showed that in patients with SCC of the vulvar, following monotherapy with pembrolizumab and regardless of PD-L1 expression level in tumor cells, a good response was created. Overall, they reported that, similar to the KEYNOTE-158 results, pembrolizumab works well ( 133 ). On the other hand, pembrolizumab can remove tumor cells due to the reinvigoration of exhausted T cells.…”

Section: Clinical Use Of Monoclonal Antibodies Against Cervical Cancersupporting

confidence: 55%

Monoclonal antibodies in cervical malignancy-related HPV

et al. 2022

View full text Add to dashboard Cite

Despite many efforts to treat HPV infection, cervical cancer survival is still poor for several reasons, including resistance to chemotherapy and relapse. Numerous treatments such as surgery, radiation therapy, immune cell-based therapies, siRNA combined with various drugs, and immunotherapy are being studied and performed to provide the best treatment. Depending on the stage and size of the tumor, methods such as radical hysterectomy, pelvic lymphadenectomy, or chemotherapy can be utilized to treat cervical cancer. While accepted, these treatments lead to interruptions in cellular pathways and immune system homeostasis. In addition to a low survival rate, cervical neoplasm incidence has been rising significantly. However, new strategies have been proposed to increase patient survival while reducing the toxicity of chemotherapy, including targeted therapy and monoclonal antibodies. In this article, we discuss the types and potential therapeutic roles of monoclonal antibodies in cervical cancer.

show abstract

Section: Clinical Use Of Monoclonal Antibodies Against Cervical Cancersupporting

confidence: 55%

Monoclonal antibodies in cervical malignancy-related HPV

et al. 2022

View full text Add to dashboard Cite

show abstract

“…All studies originated from -USA 16,18,[21][22][23][24][25][26][27][28] or Europe, 17,[29][30][31][32][33][34][35] except from one worldwide multicentre study. 36 Most studies [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] reported on women with vulvar SCC and, of these, eight studies included information on HPV status either from immunohistochemical p16 staining, 21,23,35 HPV RNA analysis, 31 or both p16 and DNA or RNA analysis. 24,29 34 One study defined HPV-positive vulvar SCCs by wildtype immunohistochemical p53 staining.…”

Section: S T U D Y C H a R A C T E R I S T I C Smentioning

confidence: 99%

“…24,29 34 One study defined HPV-positive vulvar SCCs by wildtype immunohistochemical p53 staining. 22 Most studies performed PD-L1 staining on whole-slide tissue sections, [16][17][18][21][22][23][24][25][26][27][28]30,32,33,35,36 whereas three studies used tissue microarray. 29,31,34 A variety of PD-L1 antibodies were used, of which 22C3 was the most frequent.…”

Section: S T U D Y C H a R A C T E R I S T I C Smentioning

confidence: 99%

“…29,31,34 A variety of PD-L1 antibodies were used, of which 22C3 was the most frequent. 17,[26][27][28][29][30]34,36 Nearly all studies reported PD-L1 positivity according to TPS, 16,18,[21][22][23][25][26][27][28][29][30][31][32][33][34][35] and with a threshold value for positivity classified as PD-L1 staining in ≥1% 21,23,25-28,31-34 or ≥5% 16,18,22,29,30,35 of tumour cells, respectively. In some studies, the PD-L1 TPS was categorized into different strata of positivity.…”

Section: S T U D Y C H a R A C T E R I S T I C Smentioning

confidence: 99%

“…In some studies, the PD-L1 TPS was categorized into different strata of positivity. 23,[26][27][28][31][32][33][34] Six studies assessed the PD-L1 CPS 17,23,24,27,33,36 with a cutoff point for positivity being CPS ≥1 in five studies 17,23,24,27,36 and CPS ≥10 in one study. 33 Only a few studies reported the ICS, and with different definitions.…”

Section: S T U D Y C H a R A C T E R I S T I C Smentioning

confidence: 99%

See 2 more Smart Citations

PD‐L1 expression in vulvar cancer: a systematic review and meta‐analysis

Baandrup,

Sand,

Aalborg

et al. 2023

Histopathology

View full text Add to dashboard Cite

Programmed cell death ligand‐1 (PD‐L1) expression in cancer may predict clinical response to immunotherapeutic treatment with PD‐1/PD‐L1 inhibitors. Within the vulvar cancer field, PD‐L1 expression has only been assessed by a few studies. We conducted a meta‐analysis to examine the prevalence of PD‐L1 positivity in vulvar cancer. PubMed, Embase, and Cochrane were searched for articles reporting on PD‐L1 expression in vulvar cancer. Study selection and data extraction were performed independently by two authors. We extracted data on PD‐L1 prevalence in vulvar cancer according to combined positive score (CPS) and tumour proportion score (TPS). Cutoff values for positivity were ≥1 or ≥10 for CPS and ≥1% and ≥5% for TPS. Random‐effects models were used to estimate pooled PD‐L1 prevalence, with 95% confidence intervals (CIs). Tests of between‐study heterogeneity were evaluated by the I2 statistics. Sources of heterogeneity were explored by subgroup analyses and meta‐regression. In total, 19 studies were included. Pooled PD‐L1 prevalence in vulvar cancer was 83.4% (95% CI: 70.8–91.3; I2 = 80.0) and 53.9% (95% CI: 37.4–69.6; I2 = 93.0) according to CPS and TPS, respectively. Based on TPS, human papillomavirus (HPV)‐associated vulvar squamous cell carcinomas (SCC) showed a lower PD‐L1 prevalence (39.9%; 95% CI: 13.3–74.2) compared with HPV‐independent SCC (62.6%; 95% CI: 33.7–84.6), but meta‐regression showed no significant variation in PD‐L1 prevalence by HPV status. PD‐L1 prevalence was similar in advanced (44.9%; 95% CI: 29.8–61.1) and localized vulvar cancer (56.7%; 95% CI: 18.9–76.7). In conclusion, PD‐L1 expression in vulvar cancer is frequent but between‐study heterogeneity was high. Based on a subgroup of heterogenous studies, we found no strong variation in PD‐L1 prevalence according to HPV status and stage.

show abstract